Agomab to Participate in Upcoming Investor Conferences
Agomab Therapeutics (Nasdaq: AGMB) announced that its management team will participate in four upcoming healthcare investor conferences during November and December 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Agomab Therapeutics (Nasdaq: AGMB) announced that its management team will participate in four upcoming healthcare investor conferences during November and December 2026.
Scheduled appearances include Guggenheim in Boston on November 10, Jefferies in London on November 18, Evercore in Miami on December 1, and Piper Sandler in New York on December 3. The Guggenheim, Evercore and Piper Sandler appearances are fireside chats.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Antwerp, Belgium, November 4, 2026 – Agomab Therapeutics NV (Nasdaq: AGMB) (“Agomab”), a clinical-stage biopharmaceutical company focused on fibro-inflammation, today announced that members of the management team will participate in the following upcoming investor conferences:
- Guggenheim 3rd Annual Healthcare Conference. Fireside chat on Tuesday, November 10, 2026 at 3:30 PM ET in Boston, MA.
- 2026 Jefferies Global Healthcare Conference. Wednesday, November 18, 2026 in London, UK.
- 9th Annual Evercore Healthcare Conference. Fireside chat on Tuesday, December 1, 2026 at 4:15 PM ET in Miami, FL.
- Piper Sandler 38th Annual Healthcare Conference. Fireside chat on Thursday, December 3, 2026 at 12:30 PM ET in New York, NY.
About Agomab
Agomab is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for fibro-inflammatory diseases with high unmet medical need. Agomab’s product candidates are designed to target established, potent pathways and utilize organ-restricted approaches, with the aim of increasing efficacy while minimizing safety liabilities. Fostering a culture of excellence, Agomab’s mission is to pioneer therapeutics that aim to resolve fibro-inflammation and restore organ function to enable people with these disorders to live fuller and healthier lives.
Contacts
Investors
Sofie Van Gijsel
VP of Investor Relations
E-Mail: sofie.vangijsel@agomab.com
Phone: +1 781 296 1143
Media
Gretchen Schweitzer
Trophic Communications
E-Mail: agomab@trophic.eu
Phone: +49 172 861 8540
